1	Broad neutralization of SARS-CoV-2 variants, including omicron, following
2	breakthrough infection with delta in COVID-19 vaccinated individuals
3	
4	Thomas Lechmere ¹ #, Luke B. Snell ² #, Carl Graham ¹ , Jeffrey Seow ¹ , Zayed A. Shalim ¹ ,
5	Themoula Charalampous, ² Adela Alcolea-Medina, ² Rahul Batra, ² Gaia Nebbia, ² Jonathan D.
6	Edgeworth ² , Michael H. Malim ¹ , Katie J. Doores ¹ *
7	
8	¹ Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's
9	College London, London, UK.
10	² Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases,
11	Guy's and St Thomas' NHS Foundation Trust, London, UK.
12	
13	# These authors contributed equally
14	* To whom correspondence should be addressed: katie.doores@kcl.ac.uk
15	
16	Abstract:
17	Numerous studies have shown that a prior SARS-CoV-2 infection can greatly enhance
18	the antibody response to COVID-19 vaccination, with this so called "hybrid immunity" leading
19	to greater neutralization breadth against SARS-CoV-2 variants of concern. However, little is
20	known about how breakthrough infection (BTI) in COVID-19 vaccinated individuals will impact
21	the magnitude and breadth of the neutralizing antibody response. Here, we compared
22	neutralizing antibody responses between unvaccinated and COVID-19 double vaccinated
23	individuals (including both AZD1222 and BNT162b2 vaccinees) who have been infected with
24	the delta (B.1.617.2) variant. Rapid production of Spike-reactive IgG was observed in the
25	vaccinated group providing evidence of effective vaccine priming. Overall, potent cross-
26	neutralizing activity against current SARS-CoV-2 variants of concern was observed in the BTI
27	group compared to the infection group, including neutralization of the omicron (B.1.1.529) NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

variant. This study provides important insights into population immunity where transmission
levels remain high and in the context of new or emerging variants of concern.

30

31 Introduction:

32 COVID-19 vaccines have proven to be critical in controlling SARS-CoV-2 infections 33 worldwide. Vaccines based on the SARS-CoV-2 Wuhan-1 Spike protein generate neutralizing 34 antibodies which constitute an important component of the protective capacity of COVID-19 35 vaccines. Since the beginning of the global pandemic, variants of SARS-CoV-2 have arisen 36 which encode mutations in the Spike protein. Until November 2021, the dominant circulating 37 variant was B.1.617.2 (delta), but B.1.1.529 (omicron) is rapidly increasing globally 38 (https://www.nicd.ac.za/wpcontent/uploads/2021/11/Update-of-SA-sequencing-data-from-39 GISAID-26-Nov Final.pdf). There is concern that SARS-CoV-2 variants of concern (VOCs) 40 might lead to a reduction in vaccine efficacy, in particular against omicron which encodes 31 41 amino acid changes in the Spike protein.

42 To generate high titres of Spike reactive IgG with potent neutralization, double 43 vaccination is required for both the BNT162b2 (based on mRNA encoding a stabilized Spike) 44 and AZD1222 (based on a chimp adenovirus encoded Spike) vaccines (Ramasamy et al., 45 2021; Walsh et al., 2020). Importantly, several studies have shown that SARS-CoV-2 infection 46 prior to vaccination can boost antibody titres and neutralizing activity, with this so called "hybrid 47 immunity" leading to greater neutralization breadth against SARS-CoV-2 VOCs (Goel et al., 48 2021; Manisty et al., 2021; Reynolds et al., 2021; Saadat et al., 2021; Stamatatos et al., 2021). 49 However, little is known about how breakthrough infection (BTI) in COVID-19 double 50 vaccinated individuals will impact the magnitude and breadth of the neutralizing antibody 51 response (Collier et al., 2021; Hacisuleyman et al., 2021; Kitchin, 2021), particularly in the face of the omicron variant where preliminary data shows that a 3rd vaccine dose is required 52 53 for robust neutralization activity (Cameroni, 2021; Doria-Rose, 2021; Garcia-Beltran, 2021; 54 Gruell, 2021; Schmidt, 2021) and predicted for high vaccine efficacy (Khoury, 2021). This 55 information would provide important insights into population immunity in areas where

transmission levels remain high and where omicron is rapidly becoming the dominant strain. Here, we compared the magnitude and breadth of the antibody response in individuals infected with the SARS-CoV-2 delta VOC (vaccine naïve) to the antibody response in individuals who were double vaccinated prior to delta infection (breakthrough infection, BTI).

61 **Results**

62 **Cohort description**

We identified 42 individuals admitted to St Thomas' hospital who had previously 63 64 received two COVID-19 vaccinations and subsequently tested positive for COVID-19. We note 65 that at the time of writing, from the patients admitted to St Thomas' Hospital with COVID-19 66 since the emergence of delta (n=635), 260 cases out of 332 (78%) where vaccination was 67 known were either unvaccinated or partially vaccinated (one inoculation). In this study, 30/42 68 (71%) of patients in the BTI group were admitted to hospital due to COVID-19, of which 11/30 69 (37%) patients experienced severe disease (severity 4-5). 29/30 (97%) patients had 70 underlying health conditions that predispose to severe disease and aged between 20-103 71 years (median age 77 years, IQR 59-86) (Table S1). The remaining 12 participants in the BTI 72 group (29%) were asymptomatic and admitted for reasons other than COVID-19. Patients 73 were aged between 24-96 years (median age 62 years, IQR 37-72). Overall, the BTI group 74 included individuals receiving both the AZD1222 vaccine (n = 23) and the BNT162b2 vaccine 75 (n = 19). Discarded serum samples were collected between 0-53 days post onset of symptoms 76 (POS) and longitudinal serum samples were collected where possible. The number of days 77 post second vaccine ranged from 29-179 days (median 109 days).

Sera (n = 19) were also collected from unvaccinated individuals admitted to St Thomas' hospital due to COVID-19 who had a confirmed infection with the SARS-CoV-2 delta variant and experienced a range of disease severities with 9/19 (47%) patients experiencing severe disease (severity 4-5). Patients were aged between 25-82 years (median age 39 years, IQR 30-51) and 9/19 (47%) had underlying health conditions (**Table S2**). Sera were collected between 12-22 days POS.

3

84

85 IgG and IgM to Spike in breakthrough infection

First, we measured the IgG and IgM responses to recombinant Spike (both WT and delta) in the two groups by ELISA. Sera from unvaccinated individuals infected with the delta variant at 12-22 days POS had higher delta Spike IgM levels than delta Spike IgG (**Figure 1A**) indicative of a primary immune response. Slightly higher IgG and IgM titres were observed against the delta recombinant Spike compared to WT Spike (**Figure 1B**).

91 For sera collected 12-22 days POS in the BTI group, delta Spike IgM levels in the BTI 92 group were lower than the delta Spike IgG level (Figure 1C) indicative of a recall response. A 93 similar trend was observed for both AZD1222 and BNT162b2 vaccinated individuals (Figure 94 **S1A**). Where sequential serum samples were collected, nine individuals had undetectable or 95 a very low Spike IgG response at the earliest timepoint POS (Figure 1D and Figure S1B). 96 However, high titres of Spike specific IgG were detected several days later with only modest 97 increases in IgM titres (Figure 1E-F). Six donors had IgG against Spike at early time points 98 but lacked IqG to the SARS-CoV-2 Nucleoprotein (Figure S1C-D). Although this may provide 99 insight into Spike IgG levels prior to infection, it is more likely due to a rapid Spike IgG recall 100 response compared to a de novo IgG response to Nucleoprotein (Figure 1E-F). One 101 participant (a renal transplant patient) had a high IgM response and low IgG response, similar 102 to the vaccine naïve group, which suggests failed vaccine priming (Figure 1C). Interestingly, 103 unlike the vaccine naïve group, the IgG and IgM titres against the WT and delta Spikes were 104 comparable in the BTI group (Figures 1D).

Overall, these results indicate a rapid recall response due to prior vaccination in the
 BTI group and a primary immune response in the vaccine naïve group.

107

108 Neutralization activity following breakthrough infection

109 Next, we measured neutralization breadth and potency in the two groups using HIV-1
110 (human immunodeficiency virus type-1) based virus particles, pseudotyped with SARS-CoV111 2 Spike from different VOCs (wild-type (Wuhan), alpha (B.1.1.7), delta (B.1.617.2), mu

(B.1.621) and beta (B.1.351)) and a HeLa cell-line stably expressing the ACE2 receptor (Seow et al., 2020). The majority (17/19, 89%) of the vaccine naïve group produced a robust homologous neutralizing response against the delta VOC (**Figure 2A**). Cross-neutralization of the parental strain and other VOCs was detected for most individuals, albeit at a reduced potency. As we have reported previously (Dupont et al., 2021), the greatest reduction was observed against beta with a 9.4-fold reduction in the GMT, reflecting greater antigenic distance.

119 Sera collected between 12-22 days POS from individuals in the BTI group showed a 120 robust homologous neutralizing response as well as strong cross-neutralization of the parental 121 variant and VOCs (Figure 2B). Only a 1.2-fold reduction in GMT was observed against the 122 more neutralization resistant beta VOC. Several individuals in the BTI group with sera 123 collected soon after onset of symptoms showed no or very low neutralization against both WT 124 and delta variants, however, potent neutralizing activity was detected several days later 125 (Figure 2C&D and S2A). Geometric mean titres against the five variants were very similar 126 between AZD1222 and BNT162b2 vaccinated individuals (Figure S2B). Three participants in 127 the BTI group either failed to produce neutralizing antibodies or had titres close to baseline 128 despite vaccination and SARS-CoV-2 infection. These individuals had underlying health 129 conditions including cancer (one participant was undergoing rituximab treatment) and type-2 130 diabetes.

As would have been anticipated, IgG ED₅₀ values correlated best with ID₅₀ values for the BTI group whereas IgM ED₅₀ values correlated best with ID₅₀ values for the unvaccinated group (**Figure 2E&F**) further highlighting the priming capacity of both the AZ and BNT162b2 vaccines.

135

136 BTI generates neutralizing activity against omicron

In November 2021, omicron (B.1.1.529) was identified that encoded 31 amino acid
 mutations in the Spike protein (Figure 3A). Initial studies suggest that these mutations lead
 to large reductions in neutralization of sera from double vaccinated individuals. However,

140 administration of a third vaccine dose greatly enhances neutralization titres against omicron 141 suggesting incomplete neutralization escape (Cameroni, 2021; Cele et al., 2021; Doria-Rose, 142 2021; Garcia-Beltran, 2021; Gruell, 2021; Schmidt, 2021). Neutralization activity of a subset 143 of 14 sera from the vaccine naïve group and 15 sera from the BTI group were measured 144 against WT, delta and omicron variants (Figure 3B&D). In delta infected individuals, a 28.9-145 fold reduction in GMT against omicron compared to delta was measured compared to a 6.9-146 fold reduction in GMT for WT. Sera from two participants did not neutralize the omicron variant 147 at the lowest dilution point (1:25). In contrast, all 15 sera from the BTI group neutralized the 148 omicron variant with only a 4.5-fold reduction in GMT against omicron compared to delta GMT 149 (Figure 3C&E). Three individuals showed a 21- to 81-fold reduction in ID₅₀ against omicron 150 compared to ID₅₀ against delta, all of which were receiving treatment for underlying health 151 conditions. These results further highlight the breadth of the neutralizing antibody response 152 following BTI with the delta variant.

153

154 **Discussion**

155 These data demonstrate that whilst 2-doses of COVID-19 vaccine (both BNT162b2 or 156 AZD1222) was not sufficient to provide sterilizing immunity against SARS-CoV-2 infection in 157 these particular individuals, breakthrough infection generated a strong anamnestic response. 158 Although this study cannot provide information on the titre of neutralizing antibody required for 159 protection against infection with the delta VOC, longitudinal sampling revealed that six 160 participants who had undetectable neutralization or ID₅₀ ~25 against delta VOC at the earliest 161 timepoint sampled rapidly developed IgG to Spike and serum neutralizing activity upon infection showing both AZD1222 and BNT162b2 vaccination primed their immune system to 162 163 respond rapidly upon SARS-CoV-2 infection. 30/42 (71%) of the BTI group were admitted to 164 hospital due to COVID-19 after BTI, the median age was 77 years and only 1/30 (3%) had no 165 comorbidities that would predispose to severe disease. This suggests the group admitted with 166 BTI were at particular risk of severe disease due to advancing age and/or co-morbidities. 167 Indeed, advancing age was the main criterion with which vaccination schedule was based in

168 the UK, meaning that those over 70 years were amongst the first to be offered vaccination in 169 January 2021. As such, vaccine-induced immunity may have waned in this group due to the 170 longer interval between vaccination and exposure, facilitating subsequent BTI (Levin et al., 171 2021; Mizrahi et al., 2021; Shrotri et al., 2021; Tartof et al., 2021). Indeed, the median time 172 elapsed since last vaccination in the BTI group was 109 days with 24/30 (80%) being 173 vaccinated over 10 weeks prior to symptom onset. Others have described waning of vaccine-174 induced immunity against delta after 10 weeks, especially in older age groups (Andrews, 2021; 175 Israel et al., 2021). Notably, the unvaccinated group were much younger and a large 176 proportion had no co-morbidities.

177 When comparing the immune response of the BTI group and the vaccine naïve group, 178 we observe that prior vaccination led to a more potent and broader neutralizing antibody 179 response during the acute phase of infection, including against the highly mutated omicron 180 variant. As we do not have matched sera collected prior to breakthrough infection we cannot 181 comment on the breadth of the nAb response prior to infection. However, in this vaccinated 182 cohort, boosting is occurring with a heterologous Spike which may contribute to the 183 broadening of the serum neutralizing activity. In addition, all individuals in this study received 184 an extended booster regime (8-12 weeks post prime) which has been suggested to generate 185 a broader response than the short (3-4 week) boost regime (Payne et al., 2021; Tauzin, 2021). 186 Further studies examining the antibody response at the monoclonal level is needed to 187 determine if the broader serum activity is due to individual antibodies or a de novo response 188 directed against the delta Spike. Broadening of the neutralizing antibody response has been 189 reported at later timepoints following natural infection (~6-10 months) (Dupont et al., 2021; 190 Gaebler et al., 2021) and therefore, despite narrow serum neutralization breadth in the vaccine 191 naïve group, convalescent sera collected at later timepoints would be expected to have 192 broader neutralizing activity. The large decrease in neutralization of viral particles 193 pseudotyped with omicron Spike by sera from delta infected individuals highlights the large 194 antigenic distance between the delta and omicron Spike glycoproteins (Dupont et al., 2021; 195 Liu et al., 2021).

196 Although the omicron VOC is more neutralization resistant, several studies have 197 reported smaller fold-reductions in serum neutralization potency for omicron following 3-doses 198 of COVID-19 vaccination (range 4 - 7 fold) compared to those who had received only 2 vaccine 199 doses (range 20-fold to >40-fold) (Cameroni, 2021; Doria-Rose, 2021; Garcia-Beltran, 2021; 200 Gruell, 2021; Liu, 2021; Schmidt, 2021). Overall, the data presented here suggest that a 201 breakthrough SARS-CoV-2 delta infection is also acting as an effective booster which could 202 provide broad protection against current VOCs, including omicron. As new VOCs arise with 203 new/unique combinations of mutations, our data suggests a broad neutralizing antibody 204 response generated by a combination of vaccination and infection may provide immunity 205 against other/emerging VOCs. This study provides important insights into population immunity 206 and can inform public health measures where SARS-CoV-2 transmission levels remain high. 207

208

209 Methods

210 Ethics

Collection of surplus serum samples was approved by South Central – Hampshire B REC (20/SC/0310). SARS-CoV-2 cases were diagnosed by RT–PCR of respiratory samples at St Thomas' Hospital, London. Sera were selected on the availability of longitudinal samples and knowledge of timing and type of COVID-19 vaccination.

215

216 **COVID-19 severity classification.**

217 Disease severity was determined as previously described (Dupont et al., 2021; Seow et al., 218 2020). Patients diagnosed with COVID-19 were classified as follows: (0) Asymptomatic or no 219 requirement for supplemental oxygen; (1) Requirement for supplemental oxygen (fraction of 220 inspired oxygen (FiO2) < 0.4) for at least 12 h: (2) Requirement for supplemental oxygen (FiO2) 221 \geq 0.4) for at least 12 h; (3) Requirement for non-invasive ventilation/continuous positive airway 222 not a candidate for escalation above level one (ward-based) care; (4) Requirement for 223 intubation and mechanical ventilation or supplemental oxygen (FiO2 > 0.8) and peripheral 224 oxygen saturations <90% (with no history of type 2 respiratory failure (T2RF)) or <85% (with 225 known T2RF) for at least 12 h; (5) Requirement for ECMO.

226

227 Virus sequencing

228 Delta variant infection was confirmed using whole genome sequencing as previously 229 described (Dupont et al., 2021) or using MT-PCR (Hale et al., 2021).

230

Plasmids.

WT, B.1.1.7, B.1.351, B.1.621, B.1.617.2 and B.1.1.529 codon optimized Spike plasmids were obtained from Wendy Barclay (Imperial College London). The final 19 amino acids were removed using an K1255* mutation. B.1.1.7 mutations introduced were Δ H69/V70, Δ Y144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H. B.1.351 mutations 236 introduced were D80A, D215G, Delta242-244, R246I, K417N, E484K, N501Y, D614G, 237 A701V. B.1.617.2 mutations introduced were: T19R, G142D, ∆156-157, R158G, L452R, 238 D950N. T478R. D614G, P681R, B.1.621 mutations introduced were: T95I, 239 Y144T/144insS/Y145N, R346K, E484K, N501Y, D614G, P681H, D950N. B.1.1.529 mutations 240 introduced were: A67V, Δ69-70, T95I, G142D/Δ143-145, Δ211/L212I, ins214EPE, G339D, 241 S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493K, G496S, 242 Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, 243 Q954H, N969K, L981F.

244

245 **Glycoprotein expression and purification.**

The recombinant wild-type (Wuhan-1 strain) and delta (B.1.617.2) consist of a prefusion S ectodomain residues 1–1138 with proline substitutions at amino acid positions 986 and 987, a GGGG substitution at the furin cleavage site (amino acids 682–685) and an N terminal T4 trimerisation domain followed by a Strep-tag II (Brouwer et al., 2020). Spike was expressed in HEK 293 Freestyle cells and purified using StrepTactinXT Superflow high capacity 50% suspension according to the manufacturer's protocol by gravity flow (IBA Life Sciences).

N protein was obtained from the James lab at LMB, Cambridge. The N protein is a truncated construct of the SARS-CoV-2 N protein comprising residues 48–365 with an N terminal uncleavable hexahistidine tag. N was expressed in *E. Coli* using autoinducing media for 7h at 37 °C and purified using immobilised metal affinity chromatography (IMAC), size exclusion and heparin chromatography.

258

259 Spike IgG titres by ELISA

ELISA was carried out as previously described (Seow et al., 2020). All sera were heatinactivated at 56°C for 30 mins before use in the in-house ELISA. High-binding ELISA plates (Corning, 3690) were coated with antigen (N or Spike (WT or delta)) at 3 μ g/mL (25 μ L per well) in PBS overnight at 4°C. Wells were washed with PBS-T (PBS with 0.05% Tween-20)

264 and then blocked with 100 µL 5% milk in PBS-T for 1 hr at room temperature. Wells were 265 emptied and a titration of serum starting at 1:50 and using a 6-fold dilution series in milk was 266 added and incubated for 2 hr at room temperature. Control reagents included CR3009 (2 267 µg/mL), CR3022 (0.2 µg/mL), negative control plasma (1:25 dilution), positive control plasma 268 (1:50) and blank wells. Wells were washed with PBS-T. Secondary antibody was added and 269 incubated for 1 hr at room temperature. IgM was detected using Goat-anti-human-IgM-HRP 270 (horseradish peroxidase) (1:1,000) (Sigma: A6907) and IgG was detected using Goat-anti-271 human-Fc-AP (alkaline phosphatase) (1:1,000) (Jackson: 109-055-098). Wells were washed 272 with PBS-T and either AP substrate (Sigma) was added and read at 405 nm (AP) or 1-step 273 TMB (3,3',5,5'-Tetramethylbenzidine) substrate (Thermo Scientific) was added and guenched 274 with 0.5 M H_2SO_4 before reading at 450 nm (HRP). Half-maximal binding (EC₅₀) was calculated 275 using GraphPad Prism. Measurements were carried out in duplicate.

276

277 SARS-CoV-2 pseudotyped virus particle preparation.

278 Pseudotyped HIV-1 virus incorporating the SARS-CoV-2 Spike protein (either wild-279 type, B.1.1.7, B.1.351, B.1 621, B.1.617.2 or B.1.1.529) were prepared as previously 280 described (Dupont et al., 2021). Viral particles were produced in a 10 cm dish seeded the day 281 prior with 5x10⁶ HEK293T/17 cells in 10 ml of complete Dulbecco's Modified Eagle's Medium 282 (DMEM-C, 10% FBS and 1% Pen/Strep) containing 10% (vol/vol) foetal bovine serum (FBS), 283 100 IU/ml penicillin and 100 µg/ml streptomycin. Cells were transfected using 90 µg of PEI-Max (1 mg/mL, Polysciences) with: 15µg of HIV-luciferase plasmid, 10 µg of HIV 8.91 gag/pol 284 285 plasmid and 5 µg of SARS-CoV-2 spike protein plasmid.(Grehan et al., 2015; Thompson et al., 2020) The supernatant was harvested 72 hours post-transfection. Pseudotyped virus 286 287 particles was filtered through a 0.45µm filter, and stored at -80°C until required.

288

289 Neutralization assay with SARS-CoV-2 pseudotyped virus.

290 Serial dilutions of serum samples (heat inactivated at 56°C for 30mins) were prepared 291 with DMEM media (25µL) (10% FBS and 1% Pen/Strep) and incubated with pseudotyped 292 virus (25µL) for 1-hour at 37°C in half-area 96-well plates. Next, Hela cells stably expressing 293 the ACE2 receptor were added (10,000 cells/25µL per well) and the plates were left for 72 294 hours. Infection levels were assessed in lysed cells with the Bright-Glo luciferase kit 295 (Promega), using a Victor[™] X3 multilabel reader (Perkin Elmer). Each serum sample was run 296 in duplicate and was measured against the five SARS-CoV-2 variants within the same 297 experiment using the same dilution series.

298

299 Statistical analysis.

- 300 Analyses were performed using GraphPad Prism v.8.3.1.
- 301
- 302

303 **Figures**

304



305

306

307 Figure 1: Differences in antibody binding between delta infected individuals and 308 COVID-19 vaccinated individuals experiencing delta breakthrough infection. A) 309 Difference in IgG and IgM titres for sera collected 12-22 days POS for the delta infection 310 (vaccine naïve) group. B) Comparison of the IgG and IgM ED₅₀ values against recombinant 311 WT and delta Spikes for the vaccine naïve group. Black horizontal lines show the geometric 312 mean titres. C) Difference in IgG and IgM titres for sera for the BTI group. D) Comparison of

the IgG and IgM ED₅₀ values against recombinant WT and delta Spikes for the BTI group. Black horizontal lines show the geometric mean titres. **E)** Longitudinal IgG ED₅₀ against recombinant delta Spike in the BTI group. **F)** Longitudinal IgM ED₅₀ against recombinant delta Spike in the BTI group. Donors with IgM>IgG are shown in blue, donors who do not seroconvert are shown in red, donors with high Spike IgG but no N IgG at <7days POS are shown in orange, and donors with low Spike IgG at <7 days POS that rapidly increases are shown in yellow.





321 Figure 2: Differences in neutralizing antibody response between delta infected 322 individuals and COVID-19 vaccinated individuals experiencing delta breakthrough 323 infection. ID₅₀ of neutralization against WT (black) and VOCs alpha (blue), delta (purple), mu 324 (red) and beta (orange) for sera from A) SARS-CoV-2 delta infected individuals and B) BTI 325 individuals. Black line shows the geometric mean titre. Fold decrease in GMT compared to 326 delta are shown above. Longitudinal neutralization potency of sera in BTI individuals against

327 C) WT pseudovirus particles and D) delta pseudovirus particles. Donors with IgM>IgG are 328 shown in blue, donors who do not seroconvert are shown in red, donors with high Spike IgG 329 but no N IgG at <7 days POS are shown in orange, and donors with low Spike IgG at <7 days 330 POS that rapidly increases are shown in yellow. Data for the alpha, beta and mu VOCs is 331 shown in Figure S2A. Correlation (Spearman, r) between ID₅₀ of neutralization and IgM or IgG ED₅₀ for delta Spike binding for **E**) delta infected individuals (IgM: r = 0.92, $r^2 = 0.90$, p 332 333 <0.0001 and IgG: r = 0.66, $r^2 = 0.43$, p = 0.001) and **F**) COVID-19 vaccinated individuals experiencing breakthrough infection (IgM: r = 0.61, $r^2 = 0.38$, p < 0.0001 and IgG: r = 0.83, r^2 334 335 = 0.75, p <0.0001). A linear regression was used to calculate the goodness of fit (r^2). The 336 dotted lines represent the lowest serum dilution used in each assay. IgG is shown with yellow 337 circles and IgM shown with red circles.



С









338

339 Figure 3: Neutralization of omicron in BTI and delta infected individuals. A) Schematic 340 showing mutations in the delta (B.1.617.2) and omicron (B.1.1.529) Spikes. Select sera from 341 B) SARS-CoV-2 delta infected (vaccine naïve) individuals (13-22 days POS) and C) BTI 342 individuals (12-21 days POS) was tested against WT, delta and omicron VOCs. ID_{50} of 343 neutralization against WT (black) and VOCs delta (purple), and omicron (turquoise) for each 344 participant are linked. Geometric mean titres against WT, delta and omicron VOCs for D) 345 SARS-CoV-2 delta infected individuals (13-22 days POS) and E) BTI individuals (12-21 days 346 POS). Black line shows the geometric mean titre. Fold decrease in GMT against omicron 347 compared to WT and delta are shown above.

348

349 **Acknowledgements**

350 This work was funded by; Fondation Dormeur, Vaduz for funding equipment to KJD, 351 Huo Family Foundation Award to MHM, KJD, MRC Genotype-to-Phenotype UK National 352 Virology Consortium (MR/W005611/1 to MHM, KJD), and Wellcome Trust Investigator Award 353 106223/Z/14/Z to MHM. CG is supported by the MRC-KCL Doctoral Training Partnership in 354 Biomedical Sciences (MR/N013700/1). This work was supported by the Department of Health 355 via a National Institute for Health Research comprehensive Biomedical Research Centre 356 award to Guy's and St Thomas' NHS Foundation Trust in partnership with King's College 357 London and King's College Hospital NHS Foundation Trust. This study is part of the EDCTP2 358 programme supported by the European Union (grant number RIA2020EF-3008 COVAB). The 359 views and opinions of authors expressed herein do not necessarily state or reflect those of 360 EDCTP. This project is supported by a joint initiative between the Botnar Research Centre for 361 Child Health and the European & Developing Countries Clinical Trials Partnership (KJD).

362 Thank you to Philip Brouwer. Marit van Gils and Rogier Sanders for the Spike protein 363 construct, Leo James and Jakub Luptak for the N protein, Wendy Barclay and Thomas 364 Peacock (Imperial) for providing the Spike plasmids and James Voss and Deli Huang 365 (Scripps) for providing the Hela-ACE2 cells.

366

367

medRxiv preprint doi: https://doi.org/10.1101/2021.12.01.21266982; this version posted December 21, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

368 **References**

- Andrews, N. (2021). Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. medRxiv.
- 371 Brouwer, P.J.M., Caniels, T.G., van der Straten, K., Snitselaar, J.L., Aldon, Y., Bangaru, S.,
- 372 Torres, J.L., Okba, N.M.A., Claireaux, M., Kerster, G., et al. (2020). Potent neutralizing
- antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369, 643-650.
- 375 Cameroni, E. (2021). Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron 376 antigenic shift. bioRxiv.
- 377 Cele, S., Jackson, L., Khan, K., Khoury, D.S., Moyo-Gwete, T., Tegally, H., Scheepers, C.,
- Amoako, D., Karim, F., Bernstein, M., *et al.* (2021). SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection.
- 379 incomplete escape of 380 medRxiv.
- 381 Collier, A.Y., Brown, C.M., McMahan, K., Yu, J., Liu, J., Jacob-Dolan, C., Chandrashekar, A.,
- 382 Tierney, D., Ansel, J.L., Rowe, M., *et al.* (2021). Immune Responses in Fully Vaccinated
- 383 Individuals Following Breakthrough Infection with the SARS-CoV-2 Delta Variant in 384 Province town Massachusotts mod Pxiv
- 384 Provincetown, Massachusetts. medRxiv.
- Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron
 Escape from Neutralizing Antibodies. medRxiv.
- 387 Dupont, L., Snell, L.B., Graham, C., Seow, J., Merrick, B., Lechmere, T., Maguire, T.J.A.,
- Hallett, S.R., Pickering, S., Charalampous, T., et al. (2021). Neutralizing antibody activity in
- 389 convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. Nat
- 390 Microbiol 6, 1433-1442.
- 391 Gaebler, C., Wang, Z., Lorenzi, J.C.C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A.,
- Jankovic, M., Schaefer-Babajew, D., Oliveira, T.Y., *et al.* (2021). Evolution of antibody
 immunity to SARS-CoV-2. Nature *591*, 639-644.
- Garcia-Beltran, W.F. (2021). mRNA-based COVID-19 vaccine boosters induce neutralizing
 immunity against SARSCoV-2 Omicron variant. medRxiv.
- Goel, R.R., Apostolidis, S.A., Painter, M.M., Mathew, D., Pattekar, A., Kuthuru, O., Gouma,
 S., Hicks, P., Meng, W., Rosenfeld, A.M., *et al.* (2021). Distinct antibody and memory B cell
- responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination. Sci
 Immunol 6.
 Creater K. Former, F. and Torregarter, N. (2015). An antimized method for the production of
- Grehan, K., Ferrara, F., and Temperton, N. (2015). An optimised method for the production of
 MERS-CoV spike expressing viral pseudotypes. MethodsX *2*, 379-384.
- 402 Gruell, H. (2021). mRNA booster immunization elicits potent neutralizing serum activity 403 against the SARS-CoV-2 Omicron variant. medRxiv.
- 404 Hacisuleyman, E., Hale, C., Saito, Y., Blachere, N.E., Bergh, M., Conlon, E.G., Schaefer-
- 405 Babajew, D.J., DaSilva, J., Muecksch, F., Gaebler, C., *et al.* (2021). Vaccine Breakthrough 406 Infections with SARS-CoV-2 Variants. N Engl J Med *384*, 2212-2218.
- Hale, R., Crowley, P., Dervisevic, S., Coupland, L., Cliff, P.R., Ebie, S., Snell, L.B., Paul, J.,
 Williams, C., Randell, P., *et al.* (2021). Development of a Multiplex Tandem PCR (MT-PCR)
- 409 Assay for the Detection of Emerging SARS-CoV-2 Variants. Viruses *13*.
- 410 Israel, A., Merzon, E., Schaffer, A.A., Shenhar, Y., Green, I., Golan-Cohen, A., Ruppin, E.,
- Magen, E., and Vinker, S. (2021). Elapsed time since BNT162b2 vaccine and risk of SARS CoV-2 infection: test negative design study. BMJ 375, e067873.
- 413 Khoury, D.S. (2021). A meta-analysis of Early Results to predict Vaccine efficacy against 414 Omicron. medRxiv.
- 415 Kitchin, D. (2021).
- 416 Ad26.COV2.S breakthrough infections induce high titers of antibodies capable of neutralizing
- 417 variants of concern. medRxiv.
- 418 Levin, E.G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K.,
- 419 Mendelson, E., Ziv, A., et al. (2021). Waning Immune Humoral Response to BNT162b2 Covid-
- 420 19 Vaccine over 6 Months. N Engl J Med.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.01.21266982; this version posted December 21, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

- 421 Liu, C., Ginn, H.M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., 422 Zhou, D., Mentzer, A.J., Zhao, Y., et al. (2021). Reduced neutralization of SARS-CoV-2
- 423 B.1.617 by vaccine and convalescent serum. Cell.
- 424 Liu, L. (2021). Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. 425 bioRxiv.
- 426 Manisty, C., Otter, A.D., Treibel, T.A., McKnight, A., Altmann, D.M., Brooks, T., Noursadeghi,
- 427 M., Boyton, R.J., Semper, A., and Moon, J.C. (2021). Antibody response to first BNT162b2
- 428 dose in previously SARS-CoV-2-infected individuals. Lancet 397, 1057-1058.
- 429 Mizrahi, B., Lotan, R., Kalkstein, N., Peretz, A., Perez, G., Ben-Tov, A., Chodick, G., Gazit, S.,
- 430 and Patalon, T. (2021). Correlation of SARS-CoV-2-breakthrough infections to time-from-
- 431 vaccine. Nat Commun 12, 6379.
- 432 Payne, R.P., Longet, S., Austin, J.A., Skelly, D.T., Dejnirattisai, W., Adele, S., Meardon, N., 433 Faustini, S., Al-Taei, S., Moore, S.C., et al. (2021). Immunogenicity of standard and extended 434 dosing intervals of BNT162b2 mRNA vaccine. Cell 184, 5699-5714 e5611.
- 435 Ramasamy, M.N., Minassian, A.M., Ewer, K.J., Flaxman, A.L., Folegatti, P.M., Owens, D.R.,
- 436 Voysey, M., Aley, P.K., Angus, B., Babbage, G., et al. (2021). Safety and immunogenicity of
- 437 ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults
- 438 (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 396, 1979-1993.
- 439 Reynolds, C.J., Pade, C., Gibbons, J.M., Butler, D.K., Otter, A.D., Menacho, K., Fontana, M.,
- 440 Smit, A., Sackville-West, J.E., Cutino-Moguel, T., et al. (2021). Prior SARS-CoV-2 infection 441 rescues B and T cell responses to variants after first vaccine dose. Science.
- 442 Saadat, S., Rikhtegaran Tehrani, Z., Logue, J., Newman, M., Frieman, M.B., Harris, A.D., and
- 443 Saiadi, M.M. (2021). Binding and Neutralization Antibody Titers After a Single Vaccine Dose
- 444 in Health Care Workers Previously Infected With SARS-CoV-2. JAMA 325, 1467-1469.
- 445 Schmidt, F. (2021). Plasma neutralization properties of the SARS-CoV-2 Omicron variant. 446 medRxiv.
- 447 Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K.J.A., Hemmings, O.,
- 448 O'Byrne, A., Kouphou, N., Galao, R.P., et al. (2020). Longitudinal observation and decline of
- 449 neutralizing antibody responses in the three months following SARS-CoV-2 infection in 450 humans. Nat Microbiol 5, 1598-1607.
- 451 Shrotri, M., Navaratnam, A.M.D., Nguyen, V., Byrne, T., Geismar, C., Fragaszy, E., Beale, S.,
- 452 Fong, W.L.E., Patel, P., Kovar, J., et al. (2021). Spike-antibody waning after second dose of 453 BNT162b2 or ChAdOx1. Lancet 398, 385-387.
- 454 Stamatatos, L., Czartoski, J., Wan, Y.H., Homad, L.J., Rubin, V., Glantz, H., Neradilek, M., 455 Seydoux, E., Jennewein, M.F., MacCamy, A.J., et al. (2021). mRNA vaccination boosts cross-456 variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science.
- 457 Tartof, S.Y., Slezak, J.M., Fischer, H., Hong, V., Ackerson, B.K., Ranasinghe, O.N.,
- 458 Frankland, T.B., Ogun, O.A., Zamparo, J.M., Gray, S., et al. (2021). Effectiveness of mRNA 459 BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA:
- 460 a retrospective cohort study. Lancet 398, 1407-1416.
- 461 Tauzin, A. (2021). Strong humoral immune responses against SARS-CoV-2 Spike after 462 BNT162b2 mRNA vaccination with a 16-week interval between doses. medRxiv.
- 463 Thompson, C.P., Grayson, N.E., Paton, R.S., Bolton, J.S., Lourenco, J., Penman, B.S., Lee,
- L.N., Odon, V., Mongkolsapaya, J., Chinnakannan, S., et al. (2020). Detection of neutralising 464 465 antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors 466 between March and May 2020. Euro Surveill 25.
- 467 Walsh, E.E., Frenck, R.W., Jr., Falsey, A.R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, 468 S., Neuzil, K., Mulligan, M.J., Bailey, R., et al. (2020). Safety and Immunogenicity of Two RNA-
- 469 Based Covid-19 Vaccine Candidates. N Engl J Med 383, 2439-2450.
- 470